Literature DB >> 2377207

Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region.

S J Lu1, N E Day, L Degos, V Lepage, P C Wang, S H Chan, M Simons, B McKnight, D Easton, Y Zeng.   

Abstract

The frequency of nasopharyngeal carcinoma is nearly 100-fold higher in southern Chinese than in most European populations. Earlier studies have suggested that an increased risk of nasopharyngeal carcinoma is associated with specific haplotypes in the HLA region: relative risks slightly over twofold were found for haplotypes A2, Bw46 and the antigen B17. We now report a linkage study based on affected sib pairs which suggests that a gene closely linked to the HLA locus confers a greatly increased risk of nasopharyngeal carcinoma. The maximum likelihood estimate is of a relative risk of approximately 21. The relationship between this suspected disease susceptibility gene (or genes) and known viral and environmental aetiological factors remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2377207     DOI: 10.1038/346470a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  56 in total

1.  Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles.

Authors:  S Chaudhuri; A Cariappa; M Tang; D Bell; D A Haber; K J Isselbacher; D Finkelstein; D Forcione; S Pillai
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 2.  Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000-2011: Rosetta Stone for NPC: genetics, viral infection, and other environmental factors.

Authors:  Allan Hildesheim; Cheng-Ping Wang
Journal:  Semin Cancer Biol       Date:  2012-01-25       Impact factor: 15.707

3.  Cloning and physical mapping of the HLA class I region spanning the HLA-E-to-HLA-F interval by using yeast artificial chromosomes.

Authors:  D E Geraghty; J Pei; B Lipsky; J A Hansen; P Taillon-Miller; S K Bronson; D D Chaplin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

Review 4.  Control of viral disease: the development of Epstein-Barr virus vaccines.

Authors:  A J Morgan
Journal:  Springer Semin Immunopathol       Date:  1991

5.  The complete genomic sequence of 424,015 bp at the centromeric end of the HLA class I region: gene content and polymorphism.

Authors:  T Guillaudeux; M Janer; G K Wong; T Spies; D E Geraghty
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 6.  Does East meet West? Towards a unified vision of the management of Nasopharyngeal carcinoma.

Authors:  Elaine Johanna Limkin; Pierre Blanchard
Journal:  Br J Radiol       Date:  2019-05-31       Impact factor: 3.039

7.  Role of human papillomavirus in determining the HLA associated risk of cervical carcinogenesis.

Authors:  W Z Mehal; Y M Lo; C S Herrington; M F Evans; M C Papadopoulos; K Odunis; T S Ganesan; J O McGee; J I Bell; K A Fleming
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

8.  Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis.

Authors:  Luc Friboulet; Catherine Pioche-Durieu; Sandrine Rodriguez; Alexander Valent; Sylvie Souquère; Hugues Ripoche; Abdelmajid Khabir; Sai Wah Tsao; Jacques Bosq; Kwok Wai Lo; Pierre Busson
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

Review 9.  The human leukocyte antigen class I genes in nasopharyngeal carcinoma risk.

Authors:  Elham Hassen; Ghandri Nahla; Noureddine Bouaouina; Lotfi Chouchane
Journal:  Mol Biol Rep       Date:  2009-05-17       Impact factor: 2.316

10.  HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.

Authors:  S P Lee; W A Thomas; R J Murray; F Khanim; S Kaur; L S Young; M Rowe; M Kurilla; A B Rickinson
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.